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MicroRNA-155 (miR-155) is expressed in many cancers. It also executes evolutionary conserved functions in normal B cell devel-
opment. We show that the Kaposi’s sarcoma-associated herpesvirus (KSHV) latency locus, which contains an ortholog of miR-
155, miR-K12-11, complements B cell deficiencies in miR-155 knockout mice. Germinal center (GC) formation was rescued in
spleen, lymph node, and Peyer’s patches. Immunoglobulin levels were restored. This demonstrates that KSHV can complement
the normal, physiological function of miR-155.
Like other herpesviruses, Kaposi’s sarcoma-associated herpes-virus (KSHV) employs two life cycles: lytic and latent. During
viral latency, a small set of viral genes are expressed, including
those encoding kaposin, viral Fas-associated death domain inter-
leukin-1-converting enzyme inhibitory protein (vFLIP), viral
cyclin (vCYC), latency-associated nuclear antigen (LANA), and
12 pre-microRNAs (miRNAs), called miR-K12-1 to miR-K12-12,
which give rise to up to 24 mature miRNAs (1, 2). These genes
form the KSHV latency locus. They share a promoter and are
constitutively expressed in all KSHV-infected cells (3–6). We re-
cently showed that transgenic expression of the KSHV latency
locus in mice augmented B cell response to thymus-dependent
(TD) antigen to induce chronic marginal zone (MZ) expansion,
plasma cell hyperplasia, hyperglobulinemia, and lymphoma (7).
KSHV miR-K12-11, which was part of the transgene, is an
ortholog to miR-155 (8, 9). Human miR-155 is downregulated in
KSHV-associated lymphomas, but the viral ortholog, miR-K12-
11, is highly expressed (6, 9). miR-155 is transcribed from the
non-protein-coding region of the B cell integration cluster (bic)
gene (10, 11). It is expressed in Hodgkin’s lymphoma, primary
mediastinal B cell lymphoma, and diffuse large B cell lymphoma
(10, 12, 13); miR-155 overexpression in mice led to B cell lym-
phoma (14). Ectopic expression of either miR-155 or miR-K12-11
in CD34 hematopoietic stem cells led to increased B cell expansion
in vivo (15, 16). Conversely lack of miR-155 compromised B and T
cell function, such as germinal center (GC) development (17, 18)
and reduced B cell response to TD and T cell-independent anti-
gens (19). All lymphotropic herpesviruses seem to rely on
miR-155 functions. Marek’s disease virus (MDV) miR-M4 also
functions as an ortholog to miR-155 and is required for lym-
phomagenesis in chicken (20, 21). Epstein-Barr virus (EBV) in-
duces miR-155 (22–25). This suggests that the herpesvirus miR-
155 dependency coevolved and is conserved across viruses and
across host species.
To examine if KSHV latency genes could overcome miR-155
deficiency in normal B cell function, the KSHV latency locus
transgenic mice were crossed to miR-155 knockout (miR-155ko)
mice (strain B6.Cg-Mirn155tm1.1Rsky/J) (18). Human and mouse
miR-155 are highly similar beyond the seed region and show iden-
tical end-maturation patterns (Fig. 1A). The genotype of the miR-
155 gene was ascertained by PCR (Fig. 1B). The absence of miR-
155 in miR-155ko mice was confirmed by TaqMan assay (catalog
no. 4427975; Life Technologies) (Fig. 1C and D).
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FIG 1 Generation of KSHV latency locus transgenic mice without miR-155.
(A) Sequence of human and mouse miR-155. Overlaid is the deep sequencing
coverage at each nucleotide position. This represents a new feature in mirBase
version 19, which integrates sequence coverage from multiple, previously pub-
lished RNAseq experiments. Underlined are identical residues. (B) Genotyp-
ing was done using qPCR, and PCR products were visualized via the LabChip
system (Caliper). WT, KSHV latency locus transgenic mouse; het, KSHV la-
tency locus transgene/ miR-155/ mouse; KO, miR-155/ mouse.
Shown is a representative of 3 independent experiments. (C) Expression of
mature miR-155 was confirmed by qPCR-based TaqMan assay (catalog no.
4427975; Life Technologies). A dotted or solid line represents an miR-155/
or an miR-155/ KSHV latency locus transgenic mouse. (D) Quantitative
analysis of miR-155. The expression level is expressed as percentage of U6 in
log10 scale on the vertical axis and genotype for KSHV transgene on the vertical
axis. The miR-155 genotype is shown on top of each subpanel. Shown are
individual data points in dark gray and box-whisker plots in gray. The line
indicated median expression. The limit of detection was 0.001% of U6 levels.
11908 jvi.asm.org Journal of Virology p. 11908–11911 November 2013 Volume 87 Number 21
miR-155ko mice show reduced GC B cells in gut-associated
lymphoid tissue (GALT), including in Peyer’s patches (PP) and in
mesenteric lymph nodes (mLN) but not in spleen (SP) (18). The
GC B cells were analyzed using flow cytometry. The number of GC
B cells (CD19 CD38 CD95) in PP and LN was restored to
wild-type (wt) levels in KSHV latency locus transgenic mice 
miR-155ko mice compared to miR-155ko mice not carrying the
KSHV transgene (Fig. 2A and C). This phenotype was confirmed
by histology (Fig. 2D and E). The GC area of PP in KSHV 
miR-155ko mice was larger than that of KSHV-negative miR-
155ko mice. Peanut agglutinin (PNA) is a well-validated marker
for activated GC (26–28). PNA GC B cells were increased in the
PP of KSHV  miR-155ko mice compared to in wt  miR-155ko
mice (Fig. 2F and G). The fraction of GC B cells (CD19 CD38
CD95) in SP was increased in KSHV transgenic mice  miR-
155ko animals in response to a single challenge with a T-depen-
dent antigen, (4-hydroxy-3-nitrophenyl)acetyl-chicken -globu-
lin (NP-CGG), compared to wt  miR-155ko mice (Fig. 2B).
B cells from miR-155ko animals show a lower production of
low- and high-affinity IgG1 antibodies (19) than that of wt ani-
mals. To examine if the KSHV latency locus could rescue this
phenotype, the KSHV  miR-155ko animals were immunized
with a TD antigen, (4-hydroxy-3-nitrophenyl)acetyl-keyhole
limpet hemocyanin (NP-KLH), and boosted on days 21 and 42 to
induce affinity maturation and class switching. Non-NP-specific
immunoglobulin (Ig) levels in KSHV  miR-155ko mice were
always higher than in miR-155ko mice, even in the absence of
specific immunization (Fig. 3A), indicating that the KSHV-in-
duced hyperglobulinemia (7) does not require miR-155. The
KSHV  miR-155ko mice exhibited higher NP-specific IgG re-
sponses than KSHV-negative miR-155ko mice, indicating that the
KSHV latency locus rescued miR-155 deficiency in antigen-de-
pendent B cell differentiation (Fig. 3B). This represents the first in
vivo evidence that viral latent genes can fulfill the normal function
of miR-155 in normal B cell development.
There are some limitations to this experiment. One would not
FIG 2 Rescue of miR-155 deficiency-induced phenotypes by the KSHV latency locus. Lymphocytes from KSHV latency locus transgenic mice on the miR-155ko
background (n  6) were subjected to flow cytometry analysis. miR-155ko mice (n  7) were used as a control. The percentage of GC B cells (CD19 CD38
CD95) was plotted from PP (A), spleen (B), and mLN (C). *, P  0.05. (C) KSHV latency locus transgenic mice on the miR-155ko background (n  6) and
miR-155ko mice (n  6) were immunized intraperitoneally (i.p.) with 200 g NP-CGG (Biosearch Technologies) per mouse. Percentage of SP GC B cells
(CD19 CD38 CD95) was determined on day 28 by flow cytometry. *, P  0.05. All flow cytometry data were acquired on CyAn (Beckman Coulter) and
analyzed using FlowJo (version 7.6.5; Tree Star). Two-tailed Student’s t tests were used for statistical analysis. General architecture of PP revealed by H&E staining
was shown in the transgenic (D) and wild-type (E) mice on the miR-155ko background. White arrows indicate GC area. PNA GC B cells (black arrows) were
shown in the transgenic (F) and wild-type (G) mice on the miR-155ko background. Formalin-fixed, paraffin-embedded tissue sections were stained with PNA
(Vector Laboratories). Black arrows indicate PNA GC B cells. Magnification, 40. TG means KSHV latency transgenic mice on the miR-155ko background.
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expect the single KSHV miRNA ortholog to complement all im-
munological defects associated with lack of miR-155 in vivo. For
instance, miR-155 is also required for the function of T cells (17,
18). KSHV does not normally infect T cells (30, 31), and in this
transgenic mouse the KSHV transgenes were not expressed in T
cells (26, 29). Some miR-155 targets are nonoverlapping with
miR-K12-11 and may require recognition sites beyond the seed
sequence (1, 2, 9); others are conserved among mice, virus, and
humans and so are the miR-155-dependent physiological conse-
quences (9, 32). Both KSHV miR-K12-11 and miR-155 are pres-
ent at low levels in mice, while the oncogenic phenotypes of miR-
155 and of miR-K12-11 were most evident in ectopic expression
experiments, which mimic elevated miR-155 and miR-K12-11
levels in lymphoma cells (9, 15, 16, 23). Our transgenic model
(and the miR-155ko phenotype) reflects the preneoplastic, long-
term latency of KSHV in normal B cells. Lastly, this transgenic
mouse model expresses all KSHV miRNAs as well as latent viral
proteins, which in conjunction complemented the miR-155 defi-
ciency. Studies are under way to understand the individual con-
tributions of each viral miRNA to the B cell phenotype.
Taken together, our data indicate that the KSHV latency locus
restores B cell differentiation defects associated with the lack of
FIG 3 KSHV latency locus complements reduced immunoglobulin levels in miR-155ko mice. KSHV latency locus transgenic mice with the miR-155ko
background (n  7) and miR-155ko mice (n  6) were immunized i.p. with 100 g alum-precipitated NP-KLH and boosted on day 21. Serum was collected
before immunization and on day 25. Levels of non-NP-specific (resting) and NP-specific Ig isotypes were determined using unlabeled anti-mouse Ig antibodies
(Southern Biotech) or NP34-bovine serum albumin (Biosearch Technologies). Alkaline phosphatase-labeled antibodies and p-nitrophenyl phosphate were used
for detection (all from Southern Biotech). (A) Levels of resting non-NP-specific immunoglobulins of the KSHV transgenic  miR-155ko mice (black dots, n 
7) and miR-155ko (gray triangles, n  6) were plotted, respectively. (B) Levels of NP-specific immunoglobulins of the KSHV transgenic  miR-155ko mice
(black dots, n  7) and miR-155ko (gray triangles, n  6) were analyzed 5 days after the first boost with NP-KLH and plotted. *, P  0.05.
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miR-155 in normal, precancerous B cells and allow B cells to sur-
vive and expand in the absence of miR-155. Since miR-155 is
required for GC development, one could speculate that by provid-
ing the miR-155 orthology (as well as additional functionalities),
KSHV latently drives infected B cells into the GC reaction and
beyond.
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